Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb/III study of cotadutide in non-cirrhotic NASH with fibrosis
MOH_2022-07-03_011883Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cotadutide in metabolic dysfunction-associated steatohepatitis (MASH) (8 arms), sponsored by AstraZeneca. Primary endpoints: NASH resolution without worsening of liver fibrosis at Week 48, NASH resolution without worsening of liver fibrosis at Week 84 and 1 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
cotadutide
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on MOH_2022-07-03_011883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-03_011883.